Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 3poly ICLC 2fludarabine 2belinostat 2aflibercept 2Radiosurgery 2Fluorodeoxyglucose F18 2Filgrastim 2Docetaxel 2Cyclophosphamide 2Carboplatin 2vocimagene amiretrorepvec 1tremelimumab 1trastuzumab deruxtecan 1seribantumab 1rucaparib 1romidepsin 1resiquimod 1palbociclib 1etoposide phosphate 1entinostat 1durvalumab 1ciforadenant 1cemiplimab 1cc-486 1avelumab 1amminedichloro(2-methylpyridine)platinum(II) 1Trastuzumab 1Thalidomide 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × TAS-116 × Sarcoma × Clear all
NCT05655598 2024-09-19

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

Brown University

Phase 1 Withdrawn
GenitourinaryGynecologicSarcoma

Urinary Bladder Neoplasms, Sarcoma, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡